Biogen Proceeds with Alzheimer’s Drug Trials

Biogen and its development partner Neurimmune are conducting two large-scale Phase III trials of its Alzheimer’s treatment aducanumab.

The trials come on the heels of two previous trials that showed aducanumab removed plaques from the brains of patients with early-stage Alzheimer’s disease. In the studies, plaque reduction occurred in the brain in both a dose- and time-dependent manner, according to the journal Nature.

The new trial is currently underway at more than 300 sites across 20 countries, and will assess the safety and efficacy of the drug for about 2,700 people with early Alzheimer’s disease.